Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cadonilimab |
Synonyms | |
Therapy Description |
Cadonilimab is a bispecific antibody that targets CD274 (PD-L1) and CTLA-4, potentially resulting in enhanced anti-tumor immune response (PMID: 36872527). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cadonilimab | AK-104|AK 104|AK104 | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Cadonilimab is a bispecific antibody that targets CD274 (PD-L1) and CTLA-4, potentially resulting in enhanced anti-tumor immune response (PMID: 36872527). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05063916 | Phase II | Cadonilimab | Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix | Active, not recruiting | USA | 0 |
NCT04380805 | Phase II | Cadonilimab | A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer | Completed | USA | NZL | AUS | 0 |